These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1276 related items for PubMed ID: 24190978

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
    Webb JR, Milne K, Nelson BH.
    Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
    [Abstract] [Full Text] [Related]

  • 3. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC, Wagner P, Peper JK, Schuster H, Pham DL, Greif K, Beschorner C, Rammensee HG, Stevanović S, Fend F, Staebler A.
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [Abstract] [Full Text] [Related]

  • 4. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
    Webb JR, Wick DA, Nielsen JS, Tran E, Milne K, McMurtrie E, Nelson BH.
    Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
    [Abstract] [Full Text] [Related]

  • 5. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
    Komdeur FL, Wouters MC, Workel HH, Tijans AM, Terwindt AL, Brunekreeft KL, Plat A, Klip HG, Eggink FA, Leffers N, Helfrich W, Samplonius DF, Bremer E, Wisman GB, Daemen T, Duiker EW, Hollema H, Nijman HW, de Bruyn M.
    Oncotarget; 2016 Nov 15; 7(46):75130-75144. PubMed ID: 27650547
    [Abstract] [Full Text] [Related]

  • 6. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B, Wu S, Zeng H, Liu Z, Dong W, He W, Chen X, Dong X, Zheng L, Lin T, Huang J.
    J Urol; 2015 Aug 15; 194(2):556-62. PubMed ID: 25752441
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR, Milne K, Kroeger DR, Nelson BH.
    Gynecol Oncol; 2016 May 15; 141(2):293-302. PubMed ID: 26972336
    [Abstract] [Full Text] [Related]

  • 10. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.
    Workel HH, Komdeur FL, Wouters MC, Plat A, Klip HG, Eggink FA, Wisman GB, Arts HJ, Oonk MH, Mourits MJ, Yigit R, Versluis M, Duiker EW, Hollema H, de Bruyn M, Nijman HW.
    Eur J Cancer; 2016 Jun 15; 60():1-11. PubMed ID: 27038842
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
    Koh J, Kim S, Kim MY, Go H, Jeon YK, Chung DH.
    Oncotarget; 2017 Feb 21; 8(8):13762-13769. PubMed ID: 28099920
    [Abstract] [Full Text] [Related]

  • 17. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Pinto MP, Balmaceda C, Bravo ML, Kato S, Villarroel A, Owen GI, Roa JC, Cuello MA, Ibañez C.
    Gynecol Oncol; 2018 Oct 21; 151(1):10-17. PubMed ID: 30078505
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer.
    Wang Q, Lou W, Di W, Wu X.
    Int Immunopharmacol; 2017 Nov 21; 52():7-14. PubMed ID: 28846888
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.